Diamyd Medical's CEO purchased shares in the Company
Diamyd Medical’s CEO Ulf Hannelius has purchased 20 000 Series B shares in Diamyd Medical. Hannelius’ holdings thus amount to 40 000 B-shares.
About Diamyd Medical
Diamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology.
Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Five clinical trials are ongoing with Diamyd®. An exclusive license comprising the therapeutic use of GABA in diabetes and inflammatory diseases constitutes alongside with the diabetes vaccine a key asset and the Company is developing a proprietary GABA drug product. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB and has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA.
Diamyd Medical’s B-share is traded on Nasdaq First North under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser. Further information is available on the Company’s website: www.diamyd.com.
For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41.
E-mail: ulf.hannelius@diamyd.com
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.
This information is information that Diamyd Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11:35 CET on April 7, 2017.
Tags: